- Home
- FNGR vs ALXO Comparison
FNGR vs ALXO Comparison
Compare FNGR & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNGR
- ALXO
- Stock Information
- Founded
- FNGR 2016
- ALXO 2015
- Country
- FNGR Singapore
- ALXO United States
- Employees
- FNGR N/A
- ALXO N/A
- Industry
- FNGR Computer Software: Prepackaged Software
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- FNGR Technology
- ALXO Health Care
- Exchange
- FNGR Nasdaq
- ALXO Nasdaq
- Market Cap
- FNGR 96.2M
- ALXO 102.3M
- IPO Year
- FNGR N/A
- ALXO 2020
- Fundamental
- Price
- FNGR $2.02
- ALXO $1.89
- Analyst Decision
- FNGR
- ALXO Strong Buy
- Analyst Count
- FNGR 0
- ALXO 6
- Target Price
- FNGR N/A
- ALXO $3.30
- AVG Volume (30 Days)
- FNGR 260.8K
- ALXO 752.9K
- Earning Date
- FNGR 10-13-2025
- ALXO 11-06-2025
- Dividend Yield
- FNGR N/A
- ALXO N/A
- EPS Growth
- FNGR N/A
- ALXO N/A
- EPS
- FNGR N/A
- ALXO N/A
- Revenue
- FNGR $35,692,374.00
- ALXO N/A
- Revenue This Year
- FNGR N/A
- ALXO N/A
- Revenue Next Year
- FNGR N/A
- ALXO N/A
- P/E Ratio
- FNGR N/A
- ALXO N/A
- Revenue Growth
- FNGR 11.55
- ALXO N/A
- 52 Week Low
- FNGR $1.03
- ALXO $0.40
- 52 Week High
- FNGR $5.20
- ALXO $2.27
- Technical
- Relative Strength Index (RSI)
- FNGR 70.96
- ALXO 63.29
- Support Level
- FNGR $1.55
- ALXO $1.83
- Resistance Level
- FNGR $2.20
- ALXO $2.27
- Average True Range (ATR)
- FNGR 0.13
- ALXO 0.20
- MACD
- FNGR 0.05
- ALXO 0.01
- Stochastic Oscillator
- FNGR 75.19
- ALXO 67.11
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.